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Abstract
Background: Exposure to paracetamol in the first two years of life may increase the risk of developing asthma
in childhood. Recent epidemiologic studies have identified an increased risk of asthma with paracetamol use.
Quantifying the relationship between paracetamol use and risk of asthma in children was investigated. In
previous systematic reviews and metaanalysis, results have been conflicting; studies have had inconsistent
confounders, size, and no use of control groups.
Method: An exhaustive search of all the available medical literature was conducted using 4 databases,
Medline-OVID, CINAHL, EBMR Multifile and Web of Science to identify pertinent articles. All clinical trials
and observational studies were considered. For observational studies, those that clearly defined paracetamol
exposure in the first two years of life and asthma diagnosis as a child (5-7) years were selected. Study quality
was assessed with GRADE criteria.
Results: Three birth cohort studies, and one multicenter cross-sectional ranging from 469 to 205 487
participants, from birth up to two years of life were included in the review that were later followed up between
5-7.5 years of age. In the large multicenter study after adjustments for sex, region of world, language and
income, multivariate analysis with complete data only and risk of asthma in childhood and total days of
paracetamol use in early life for fever was (OR 1.46 [95%CI 1.36-1.56]). In the largest birth cohort when
adjusted for maternal factors in pregnancy and postnatal factors there was no significant effects of paracetamol
use and childhood asthma (OR 1.11 [95%CI 1.00-1.23]). In this same study when children who had
preexisting wheeze versus no wheeze, and effects of paracetamol and childhood asthma, there was a significant
association for child with wheeze (OR 1.44[95%CI 1.13-1.83]). When adjustments were made for frequency
of respiratory tract infections and total days of paracetamol use any indication in the other smaller birth
cohort, there was no significance in a child with family history of atopy (OR 1.08 [95% CI 0.91-1.29]). In the
smallest of studies included, after adjustments for chest infections, antibiotic use, and family history of atopy,
there was no significance of childhood asthma and exposure to paracetamol (OR 1.78[95%CI .75-4.21]).
Conclusion: The results from the review are inconsistent. It is suggested that exposure to paracetamol in the
first years of life might be a risk factor for the development of asthma in childhood and direct causation is still
questionable. Results do suggest that children with family history of atopy, or current asthma, and the use of
paracetamol may precipitate asthma. Future RCT studies are needed.
Keywords: Paracetamol, acetaminophen, asthma, child, infant.
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 Abstract   
Background: Exposure to paracetamol in the first two years of life may increase the risk 
of developing asthma in childhood. Recent epidemiologic studies have identified an 
increased risk of asthma with paracetamol use. Quantifying the relationship between 
paracetamol use and risk of asthma in children was investigated. In previous systematic 
reviews and metaanalysis, results have been conflicting; studies have had inconsistent 
confounders, size, and no use of control groups. 
Method: An exhaustive search of all the available medical literature was conducted using 
4 databases, Medline-OVID, CINAHL, EBMR Multifile and Web of Science to identify 
pertinent articles. All clinical trials and observational studies were considered. For 
observational studies, those that clearly defined paracetamol exposure in the first two 
years of life and asthma diagnosis as a child (5-7) years were selected. Study quality was 
assessed with GRADE criteria. 
 
Results:  Three birth cohort studies, and one multicenter cross-sectional ranging from 
469 to 205 487 participants, from birth up to two years of life were included in the review 
that were later followed up between 5-7.5 years of age. In the large multicenter study 
after adjustments for sex, region of world, language and income, multivariate analysis 
with complete data only and risk of asthma in childhood and total days of paracetamol 
use in early life for fever was (OR 1.46 [95%CI 1.36-1.56]). In the largest birth cohort 
when adjusted for maternal factors in pregnancy and postnatal factors there was no 
significant effects of paracetamol use and childhood asthma (OR 1.11 [95%CI 1.00-
1.23]). In this same study when children who had preexisting wheeze versus no wheeze, 
and effects of paracetamol and childhood asthma, there was a significant association for 
child with wheeze (OR 1.44[95%CI 1.13-1.83]). When adjustments were made for 
frequency of respiratory tract infections and total days of paracetamol use any indication 
in the other smaller birth cohort, there was no significance in a child with family history 
of atopy (OR 1.08 [95% CI 0.91-1.29]). In the smallest of studies included, after 
adjustments for chest infections, antibiotic use, and family history of atopy, there was no 
significance of childhood asthma and exposure to paracetamol (OR 1.78[95%CI .75-
4.21]). 
Conclusion: The results from the review are inconsistent. It is suggested that exposure to 
paracetamol in the first years of life might be a risk factor for the development of asthma 
in childhood and direct causation is still questionable. Results do suggest that children 
with family history of atopy, or current asthma, and the use of paracetamol may 
precipitate asthma. Future RCT studies are needed.  
Keywords: Paracetamol, acetaminophen, asthma, child, infant. 
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Paracetamol Use in Early Life and Link to Childhood Asthma: A Systematic Review 
BACKGROUND 
Asthma has become one of the most common disorders among children. Reasons 
for the increase in asthma over recent decades and international patterns of asthma 
prevalence are poorly understood and cannot be adequately explained by current 
knowledge of the causation of asthma.1  Epidemiologic studies have demonstrated a 
higher prevalence of asthma in more developed countries than developing countries.2,3 
This has led to the investigation of the role of risk factors that may increase susceptibility 
to the development of asthma. Attracting recent interest, but lacking study support, is the 
hypothesis that paracetamol (commonly named acetaminophen in the United States) use 
might increase the risk of asthma.  
Other risk factors and possible causes of asthma in the first years of life that have 
been investigated include: respiratory infections, family history or early childhood atopy 
symptoms, antibiotic use, pollution, and toxins. Respiratory infections are among the 
more known substantial risk factors for asthma and are important contributors to clinical 
indices for the predictions of asthma risk in childhood. As well as a common reason for 
ingesting paracetamol.4-6 Moreover, dietary changes are a suspect, with a decrease in 
antioxidant rich diets, reducing levels of pulmonary antioxidants and making the lungs 
more susceptible to oxidative stress.7 Interesting enough, there has been a link to 
pharmaceutical sales of paracetamol and the asthma epidemic.8 Despite major research 
efforts and the importance of these many risk factors in development of asthma, the exact 
cause of asthma still remains uncertain.9-11 
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Evidence to date implicating paracetamol in the etiology of asthma has been 
consistent with adverse effects reported in paracetamol exposure in utero,12 during 
infancy,13,14 in childhood,15,16 and during adult life.17-20 These studies previously 
mentioned have relied on retrospective data collection and failed to account for and 
adjust for common confounders leading to inconsistencies.12-20  
Patacetamol is the preferred drug to relieve pain and fever in children under 6 
months of age.21 Some evidence may suggest that ingestion of paracetamol early in life 
may cause asthma.18,20,22-24 Possibly the shift from aspirin to paracetamol use may have 
contributed to the rise in childhood asthma. Paracetamol use became prevalent when it 
replaced aspirin particularly in children at risk for Reyes syndrome, which can damage 
the brain and liver, with the use of aspirin to treat chickenpox and flu in infants. 
Paracetamol emerged as the safer alternative for children at this time. Since that time, the 
increase of incidence of asthma in the US went from 3.6% to 5.8% and similar increases 
were seen throughout the world.16,25 Time may be revealing paracetamol’s danger, its use 
has parallelled the rise in asthma prevalence in children. Along with other factors such as 
a decrease in physical activity, increase in obesity and the amount of time spent indoors, 
and increase in the use of group daycare.16,26 The trend is noteworthy that asthma 
prevalence leveled off in the 1990’s when paracetamol was already the most common 
used analgesic for children.16 In addition to risk factors coexisting with paracetamol 
intake, it may be contained under multiple names or combinations. Paracetamol was 
found under 64 names in the Kang et al study.27 These factors have resulted in much 
confusion in determining if paracetamol causes asthma. 
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Paracetamol use has three common proposed mechanisms for causing asthma.25,28 
It has been thought to be a risk for asthma because this agent induces depletion of 
antioxidant rich glutathione in lung tissue. Oxidative damage to the lungs may occur 
more readily and low glutathione levels may lead to defective antigen processing, thereby 
promoting the Th2 allergic pathway during a critical time in immune system 
development.29 This process might be critical to consider when giving paracetamol to a 
young child with under developed lungs during a respiratory infection. Secondly, there 
may be higher production of prostaglandin E2 and suppression of the COX-2 receptor, 
both of which favor the Th2 allergic pathway over a Th 1 immune response. Furthermore, 
this impaired Th1 response, can result in an inability to clear infections.30 Thirdly, the 
paracetamol molecule has similar molecular weight to chemicals known to cause asthma 
from occupational exposures.28  
A systematic review was conducted in 2008 which looked at 8 studies in children 
and their exposure to paracetamol and incidence of wheeze or asthma.31 It concluded that 
the results were consistent with an increase in the risk of asthma in children and adults 
with early and concurrent paracetamol use and it was recommended that future studies 
are needed.  
Dr. John T. Mcbride, in a recent report for PEDIATRICS, the Official Journal of 
the American Academy of Pediatrics (AAP), sends a warning about paracetamol and its 
relationship with asthma. He stated in the December 2011 issue32 that “I need further 
studies not to prove that acetaminophen is dangerous but rather to prove that it is safe," 
McBride concludes in his report. "Until such evidence is forthcoming, I will recommend 
avoidance of acetaminophen by all children with asthma or those at risk of asthma.”32 
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This is a powerful statement and warrants attention to determine if paracetamol use in 
early life causes asthma. 
Therefore, the aim of this systematic review was to determine if recent research 
since the last systematic review,31 has been conducted and to establish what the 
relationship is between the use of paracetamol early in life and the incidence of childhood 
asthma. This review will help guide our prescribing of paracetamol, and make patients, 
parents and primary care providers aware of the possibility that paracetamol exposure 
may have dangerous side effects. 
METHOD 
         An exhaustive search of the medical literature was conducted using 4 databases, 
Medline-OVID, CINAHL, EBMR Multifile and Web of Science. The following terms 
were used to narrow the search: “paracetamol/paracetamol and asthma”, and “infant or 
child”. Duplicates were removed. The search was then narrowed using the following 
eligibility criteria: inclusion of articles in the English language, on human subjects, and 
published after the year 2008. Studies were also excluded if they were not relevant or did 
not evaluate paracetamol ingestion in the first 2 years of life and incidence of asthma in 
childhood. For this review childhood was defined as 5-7 years old, which asthma 
symptoms at this age have been shown to predict adult asthma.33 The works cited of the 
articles were further searched for relevant sources. The articles in this review were 
assessed for quality using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) developed by the GRADE Working Group.34 
RESULTS 
           Initial result of the search yielded 206 articles for review. One hundred thirty three 
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articles were excluded as duplicates, leaving 73 articles. After exclusions were applied 
only 4 studies were included in qualitative synthesis. These articles included 3 birth 
cohort, and one multicenter, cross sectional study used for its strength in numbers. 
Lowe et al 
In this prospective birth cohort study,35 paracetamol use in early life and asthma 
was assessed in 620 infants. They were recruited before birth and enrolled in the 
Melbourne Atopy Cohort Study. Infants were eligible to be enrolled if one or more of 
their first degree family members had eczema, asthma, allergic rhinitis, or severe food 
allergy. A telephone survey was performed every four weeks until the age of 64 weeks, 
then 78 weeks, and age of 2. An annual telephone interview was performed from 3 to 7 
years of age. Illnesses since previous interview, oral exposures to food or medicine, 
including paracetamol, were all documented. The classification of indications for the 
exposure to paracetamol was tracked, to include number of episodes, days of use, and 
reason for administration. These were recorded for each exposure. For each child the 
classified reason for use of paracetamol for each episode of illness was put into one of 
four categories. Parental report of contact with medical professionals for infection was 
also documented. The number of days of exposure to paracetamol for each child 
regardless of dose or frequency within the first two years of life was recorded, including 
any preparation that contained paracetamol. Current childhood asthma for this study was 
defined as one or more episodes of asthma diagnosed by a family physician in the 
previous 12 months, this was the primary outcome. Infantile wheeze was a parental report 
of a doctor diagnosis of an asthma-like condition before 2. Standard confounders adjusted 
for were infants sex, parental history of asthma or eczema, and presence of older siblings 
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at the time of birth. The final model made adjustments for frequency of medical contact 
for infections (otitis media, upper respiratory tract infection, bronchitis, and 
gastroenteritis).35 
Twenty five were lost to follow up, 14 refused, 6 missed but rejoined later. A total 
of 495 completed follow up at 6 or 7 years or both. A questionnaire at 6 or 7 years was 
filled out to ascertain childhood asthma or other atopic conditions, allergic rhinitis, 
eczema, and indications for paracetamol use was also tracked, lower or upper respiratory 
tract symptoms, non respiratory illness or any indication. Associations between total days 
of paracetamol use for any indication during early life and risk of allergic disease, as well 
as associations between paracetamol intake for non respiratory causes during early life 
and risk of allergic disease later in childhood were adjusted for.35 
During the first two years of life 97% of infants received paracetamol, on average 
the median total number of days of exposure was 17, and most, 537, were exposed to 
paracetamol for non respiratory illness. The next most common reason for use was upper 
respiratory tract symptoms, 510. At age 6-7 29.9% had current childhood asthma 
diagnosed as described earlier by a doctor. Children who had current childhood asthma or 
allergic rhinitis total number of days of paracetamol use in the first two years was slightly 
higher. The unadjusted regression analysis showed a greater number of days of 
paracetamol exposure (all cause), had increased risk of childhood asthma OR 1.18 (1.00-
1.39). Adjustment for standard confounders in this study did not alter observed 
associations. Adjustment for frequency of respiratory tract infections strengthened the 
association with childhood asthma 1.08 (.91-1.29), leaving no evidence of an independent 
association of asthma and infantile paracetamol use.35 
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There was no evidence of any association between paracetamol use for non 
respiratory illness and risk of any allergic disease outcome. Paracetamol use for lower 
respiratory tract illness (defined as infantile wheeze, bronchitis, drugs for lower 
respiratory tract illness) when compared to upper respiratory tract illness was strongly 
associated with increased risk of childhood asthma OR 1.49 (1.25-1.78), 244 children had 
lower respiratory tract symptoms, 43% received paracetamol for the symptoms. When 
analysis was restricted to the subgroup who had lower respiratory tract symptoms, 
minimal evidence that any use category 1.16 (.68-1.98) or frequent use 1.12 (.91-1.38) 
for lower respiratory tract symptoms was associated with increased risk of childhood 
asthma.35 
Paracetamol use for upper respiratory tract symptoms was associated with 
increased risk of childhood asthma OR 1.20 (1.05-1.38). Only 2.4% of children did not 
have upper respiratory tract symptoms within the first two years of life. The number of 
events of upper respiratory tract symptoms strongly related to increased risk of childhood 
asthma, when adjusted, days of paracetamol use for upper respiratory tract symptoms, for 
number of events, the evidence of association was strengthened 1.10 (.95-1.28).35 
The authors concluded consistent results with previous studies in this area, finding 
evidence of a weak or “crude” association between paracetamol use in early life and 
increased asthma. Lowes et al study classified indications for exposure to paracetamol, it 
showed no evidence of association after adjustments were made for history of early 
infections, or when association was limited to paracetamol use for non respiratory tract 
illness. Although use of paracetamol for lower respiratory tract infections and wheeze 
was associated with increased risk of allergic disease, increasing days of use did not 
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increase risk of allergic disease. It was concluded by the authors that paracetamol use in 
early life is not an independent risk factor for childhood asthma.35 
Beasley et al 
  This study36 was a multicenter, cross sectional study of school children, and the 
association between paracetamol use in infancy and childhood and the risk of asthma. 
International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three studied 
6-7 year old children, a multicountry cross sectional study, who were chosen from a 
random sample of schools in defined geographical areas. Standardized questionnaires 
(see Appendix) were completed by the parents or guardian, the first being about asthma 
symptoms and the second an environmental questionnaire about possible protective and 
risk factors for development of allergic disease. Demographic information was gathered 
and paracetamol use in the first year of life and in the past 12 months was obtained. 
Questionnaires when necessary were translated into the local language. A positive 
response was referred to as reported use of paracetamol for fever in the first year of life. 
Symptom of wheeze were identified by a positive answer to the question “Has your child 
had wheezing or whistling in the chest in the past 12 months?” Severe asthma symptoms 
were identified by one or more answers to “How many attacks of wheezing has your 
child had in past 12 months?” The study sponsors had no role in study design, data 
collection, analysis, data interpretation, writing of the report, or in the decision to submit 
the paper for publication. The authors were responsible to write and submit the 
manuscript for publication with the ISAAC Phase Three Steering Group.36 
To date this is the largest study to consider this question, 205 487 children, 73 
centers, and 31 countries, 194 555 children aged 6-7 from 69 centers in 29 countries were 
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included in the analysis of paracetamol use for fever during first year of life. Multivariate 
analysis included 105 041 children, 47 centers, 20 countries. To be included in the 
analysis, centers had to assess at least 1000 children and have a response rate of more 
than 60%. Analysis of all study participants were adjusted for sex, region of world, 
language, and gross international income. Analyses were done separate for paracetamol 
use in first year of life and at 6-7 years. In the multivariate analysis, children who had a 
missing value for any of the covariates (maternal education, antibiotic use in first year of 
life, ever breast fed, parental smoking, current diet, and siblings) were removed.36 
Reported results were that use of paracetamol was associated with a significantly 
increased risk of asthma symptoms, the risk was similar in all children, and in those with 
complete covariate data, 1.76 (1.68-1.85) and 1.77 (1.66-1.89) respectively. In the 
multivariate analysis, the reported use of paracetamol for fever in the first year of life was 
also associated with a significantly increased risk of current asthma symptoms, 1.46 
(1.36-1.56). The risk of asthma symptoms was increased in different countries 
worldwide, p value for homogeneity between regions was <0.005. For the 47 centers 
combined, the population attributable risk for asthma symptoms due to paracetamol use 
for fever in the first year of life was 21%. The reported use of paracetamol for fever in 
the first year of life was also associated with a significantly increased risk of severe 
asthma symptoms, adjusted 1.82 (1.70-1.95), complete covariate data 1.82 (1.65-2.00), 
and multivariate 1.43 (1.30-1.58). The increase in the risk for severe asthma symptoms 
was similar to that for current wheeze. In the 47 centers combined, the population 
attributable risk for severe asthma symptoms due to paracetamol use for fever in the first 
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year of life was 22%. This study also reported paracetamol use in the past 12 months, and 
current use. This data will not be reviewed in this study.36 
The authors concluded from this study that the use of paracetamol for fever in the 
first year of life is associated with symptoms of asthma in childhood worldwide. 
Associations between use of paracetamol in the first year of life and the risk of severe 
asthma symptoms with population attributable risks were also identified. Causality 
cannot be established from a study with this design, the authors “suggest that exposure to 
paracetamol might be an important putative risk factor for the development of asthma.” 
They also state evidence is insufficient to advise parents and health care workers of the 
risk benefit of taking paracetamol in childhood, or its comparative efficacy and safety 
with other approaches. Further research was also advised.36 
Wickens et al 
            This study37 was a birth observational study that reported paracetamol exposure 
between birth and 15 months, data was collected during this time and between 5-6 years 
of age. This was part of the New Zealand Asthma and Allergy Cohort Study, mothers 
were recruited during pregnancy through a random sample of midwives in Wellington 
and Christchurch New Zealand. Study nurses administered questionnaires at recruitment, 
3 and 15 months, and yearly until 6 years. Family history of the person completing the 
questionnaire, usually the mother was collected, and questions about the biological father 
were asked only if he was part of the household.  Adjustments were made for family 
history, 11 households were excluded where the father was absent, and participants with 
missing data were not entered. Participants were assessed in their home at 3 and 15 
months, and at the research facilities in each center at 6 years. At each contact, 
 17 
prevalence of wheeze, hayfever, rhinitis symptoms, and eczema were assessed using the 
standard questions from the ISAAC questionnaire (See Appendix A). The recall period 
was restated as, since the last questionnaire to ensure continuity of data. Prevalence rates 
of diagnosed asthma were reported as history of diagnosed asthma ever, plus a reported 
history in last 12 months of either wheeze or inhaler use, or both. The indicators of severe 
asthma symptoms were speech limiting wheeze and sleep disturbance due to wheeze. 
Children with non severe wheeze were classified together with children without wheeze, 
as non–cases. Wheeze was characterized as transient (only in first 3 years), late onset 
(wheeze occurring between 3 and 6 only), persistent (in the first 3 years of life and 
between 3 and 6 years), and never. Atopy conditions were assessed with skin prick 
testing and serum samples obtained analyzing IgE, these test results will not be 
investigated further in this review.37 
            At 3 and 15 months, only the Christchurch center had collected data on whether 
or not paracetamol had been used. The Wellington center had commenced the study 
before the paracetamol hypotheses. At 6 years, the number of doses of paracetamol taken 
during the last 5 years was collected. The Christchurch center recruited 553 subjects, 535 
at 3 months, 505 at 15 months, and 473 at 6 years. Data at both 15 months and 6 years 
was 469 (84.8%) of recruited participants. Among the Christchurch center children, 
89.9% had received at least one dose of paracetamol by 15 months of age. Models were 
constructed for paracetamol exposure from birth to 15 months, and adjusted for number 
of chest infections and systemic antibiotics, gender, family history, parity, birth weight, 
maternal age, maternal smoking during pregnancy and any household exposure to 
smoking or second hand smoke.37 
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            The odds ratios (OR) were elevated for effects of early paracetamol use on current 
asthma and wheeze at 6 years, adjusted OR 1.78 (.75-4.21), and strengthened in the 
subgroup with atopic current asthma, adjusted OR 4.13 (.93-18.48), with both almost 
reaching significance. The number of participants meeting severe asthma symptoms and 
criteria were too small to analyze. Both environmental tobacco smoke and paracetamol 
may influence the development or severity of asthma through depleting glutathione 
levels.38 Results of whether or not environmental smoke (as a independent risk factor) at 
15 months modified the relationship between paracetamol and wheeze were analyzed, but 
found no significant interactive effect (P=.53).37 
            The authors of this study concluded that children in the Christchurch center who 
had used paracetamol before 15 months (89.9%) were more than three times likely to be 
atopic at 6 years than children not using paracetamol in infancy. The effects of 
paracetamol on current asthma or wheeze at 5-6 years old although elevated, were not 
statistically significant before and after adjustments. Direct causation has not been 
established and the maintenance of asthma symptoms with paracetamol. 37 
Shaheen et al 
            This is a population based birth cohort39 that recruited 14 541 pregnant women 
residing in Avon, United Kingdom, which is also referred to as the Avon Longitudinal 
Study of Parents and Children, (ALSPAC) cohort. Of these births, 13 988 of these 
children were alive at age 1 year and followed up. The cohort has been followed since 
birth with annual questionnaires and until age 7 years with objective measures in annual 
research clinics. At six months after birth, mothers were asked how often they had given 
their infant paracetamol since birth (never, once, more than once). Additional information 
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was gathered during intrauterine including genotyping, this data and studied results will 
not be discussed in this review. Only specific data collection and studied results that met 
the search criteria from this study will be included.39 
            When children were 7.5 years old mothers were asked, “Has your child had any of 
the following in the past 12 months: wheezing, asthma, eczema, hay fever?” Children 
were defined as having current doctor diagnosed asthma at 7.5 years if mothers 
responded positively to the question, “Has a doctor ever actually said that your study 
child has asthma?” and mom had responded positively to 1 or both of the questions on 
wheezing and asthma in the past 12 months. Paracetamol exposure in infancy propensity 
scores were defined by a list of confounders as predictive factors, the propensity score for 
this study was a measure of paracetamol proneness of infants based on a list of 
confounding variables: maternal factors during pregnancy, smoking infections, anxiety 
score, antibiotic use, alcohol intake educational level, housing tenure, financial 
difficulties, BMI, ethnicity, age, parity, history of asthma, eczema, rhinoconjunctivitis, 
migraine, sex of child, season of birth, multiple pregnancy, gestational age, birth weight, 
head circumference, birth length, and postnatal factors breast feeding, day care, pets, 
damp/mold, environmental tobacco smoke exposure, number of younger siblings, and 
BMI at age 7. In the analyses of infant paracetamol exposure, maternal paracetamol use 
in pregnancy and use of antibiotics in the first 6 months after birth were controlled for 
and the confounders used to generate aforementioned paracetamol propensity scores.39 
Of 11 438 infants with data on infant paracetamol use, 14% had not received the drug in 
the first 6 months after birth, 20% were given it once, 66% were given it on 2 or more 
occasions. The unadjusted effects of infant paracetamol use on childhood asthma was 
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1.19 (1.08-1.32), and adjusted was 1.11 (1.00-1.23). When controlled just for prenatal 
paracetamol exposure the association between infant use and asthma was attenuated a 
little, OR reduced from 1.19-1.16. After controlling for all confounders, infant use was 
associated with an increased risk of childhood asthma. When stratified, the risks of 
asthma were greater in children who wheezed in infancy39 1.44 (1.13-1.83).  
            The authors concluded that a longitudinal association with childhood asthma was 
independent of prenatal paracetamol exposure. It was limited to children who had 
wheezed in infancy, most likely explained by the fact that infants who already have a 
wheezing tendency are more likely to be given paracetamol for viral respiratory 
infections with fever. The authors also recommend confirmation of data with 
experimental studies in animals, which could provide supportive evidence, with human 
studies as definitive evidence. They recommended randomized controlled trials (RCT) 
which have their own challenges.40 
DISCUSSION 
            Implications for practice are still unclear. Findings were not significant for 
childhood asthma when adjusted in the infant exposure group for infections and other 
confounders. There was significance in the exposure group when not adjusted for 
indication of use, frequency and dosing, and specificity of febrile illness. It is unknown if 
the benefits outweigh the risks. Of the four articles included in this systematic review, the 
overall combined quality of evidence as evaluated by GRADE is very low. At this time a 
weak recommendation is warranted. Paracetamol should be used with caution and 
sparingly to the infant with preexisting wheeze or risk of asthma under six months of age 
as described by the Shaheen et al study.40 In children up to 2 with family history of atopy 
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that are currently asymptomatic, there is no significant difference in childhood asthma 
with use of acetamionophen as shown by Lowe et al.41 It should be clear that results from 
the present studies reveal that paracetamol has no beneficial effect on disease outcomes 
when used as an antipyretic. Is it worth taking unknown risks without knowing 
alternative benefits of treatment? 
Current clinical practice should question the indications of use for paracetamol 
and what the risks are. In considering the risks and benefits of paracetamol use with the 
need for clearly stated implications in practice from studies, moving forward with its use 
should be done with caution. With some studies suggesting indications of precipitating 
asthma prevalence in adolescence, and the weak correlation of causing asthma symptoms, 
the suggestions from McBride last month in PEDIATRICS are warranted.32 Treating 
current asthmatic infants and children and those who are at risk for developing asthma 
should be done with caution and not at all when possible when choosing paracetamol as 
the analgesic or antipyretic of choice. Guidelines for its indication of use are unclear. Its 
use in febrile illness needs further investigation. Confounders of prenatal use, concurrent 
antibiotic use, infection rate, particularly respiratory infections as a risk factor for asthma 
need to be researched. A family history of atopy or current symptoms of allergic disease, 
along with other risk factors need to be considered also. 
Lowe et al41 demonstrated that after making adjustments for frequency of 
infections, there was no significance when compared to the unadjusted group for 
paracetamol exposure. To be included in this study the child must have had a first degree 
relative with history of atopy or allergic disease, this could have limitations in eligibility 
criteria for the study. All participants were exposed to at least one dose of paracetamol 
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with no control due to the nature of the observational study. Frequency of exposure to 
paracetamol and indication of use were important outcomes considered in this study and 
demonstrated a strength of design. There was less recall bias with the prospective design 
of this study and frequent follow up. Confounders were controlled for all participants and 
considered in the indication of use analysis so the results were able to be adjusted for 
frequency of infections and standard adjustments. The evidence reported by Lowe et al 
for any indication and non respiratory causes were examined, when confounders were 
adjusted there was no significant difference in paracetamol exposure. This is the only 
study in the review that offered valuable data of indication of use and adjustment for 
respiratory infections that is a known risk factor for asthma. The evidence from this study 
does not support the conclusion that paracetamol exposure is a causal factor for asthma.41 
However, this study is not without limitations. Since this study only included 
children with family history of atopy, the results need to be applied to the general 
population with care. Another limit to this study is that parental report of asthma 
symptoms is relied upon as opposed to a doctor diagnosis of asthma. This could be a 
weakness or strength, minimizing bias and differences in healthcare practices in some 
cases, or some cases of asthma may have been missed. As with other birth cohort 
observational studies in the review, no use of placebo was possible, it is anticipated that 
there would be widespread non compliance, and it may be unethical to ask participants to 
not use paracetamol with their infant. As an observational study, this study started off 
with a low GRADE quality of data. This study received a downgrade for failure to 
include control population, selection of biased exposed group with atopy, and confidence 
intervals when adjustments were made include no effect or appreciable benefit or harm. 
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This study receives an upgrade for its use of relevant confounders adjusted for in 
analyzing risk of asthma. The quality of evidence in this study was then given an overall 
GRADE of very low, with an overall significance rating of “critical”. 
Beasley et al36 demonstrated that use of paracetamol for fever in the first year of 
life was associated with an increased risk of asthma symptoms with a multivariate 
analyses. The evidence reported supports the hypothesis that paracetamol presents as a 
risk factor for asthma. The strengths of this study were its power, size, and its 
multinational nature. This study received an upgrade for having such a large sample size. 
It was included in this review for these purposes and it met inclusion criteria but it should 
be noted that it is the oldest of the studies considered with the fewest confounders. This 
study did not look at indications of use for paracetamol, respiratory infections in early 
life, specifically a known risk factor for asthma.  Due to the nature of the study, recall 
bias could exist, and it should be considered that parents of children with asthma are 
more likely to report paracetamol use. Frequency or dose response in the first year of life 
was not examined, only current frequency of use was looked at. Current use of 
paracetamol was associated with a dose dependent increased risk of asthma symptoms. 
Although a surrogate outcome of interest, this deserves an upgrade of one. Because of the 
nature of this large multinational study, it should be considered that paracetamol comes in 
different names and combinations. Off label use and dosing differences internationally 
were not considered. English translation of questionnaires could have affected the 
validity of the study when interpreted. Parental report of asthma symptoms could have 
excluded or included participants. Due to the observational nature of this study it started 
off with a low GRADE quality of data. This study received a single downgrade for 
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having no control group, lack of relevant confounders, no information on indication for 
use, and questionable validity with translation of questionnaires. It should be noted that 
no adjustments or considerations were made for the use of different names for 
paracetamol or combinations of it internationally, or its off label use.36 
There was little or no bias by limiting the multivariate analysis to children with 
complete covariate data, greater than 70%. Sensitivity analyses were performed adjusting 
the association between paracetamol use for fever in the first year of life and symptoms 
of asthma later in childhood for paracetamol use in the past 12 months and vice versa.36 
Although indications for use in infancy were not analyzed it should be noted that 
paracetamol use for febrile illness was indicated, there are many causes of febrile illness 
in infancy, including respiratory tract illness, and unrelated illnesses to respiratory tract, 
paracetamol use for such episodes could cause confounding in this study. 
Questionnaires were translated to native language and then back to English, completed by 
parents, and retrospectively gathered, which contribute to the recall bias. Poor recall 
could reduce the ability to measure any effect of paracetamol, and there were no 
differences in parents of children with asthma than those without when adjustments were 
made. No emphasis was given to a paracetamol question in the ISAAC study 
questionnaire (see Appendix A), eliminating source of bias. Parent reported symptoms of 
asthma were used.  This was explained in this large study in developed and undeveloped 
countries to avoid major diagnosis differences related to access to medical care, language 
barrier, and medical practice population changes. Since all important plausible 
confounding were not considered, the demonstrated association between paracetamol use 
and asthma was overestimated. This will decrease the quality of evidence by one. 
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The data from this study has contributed to establishing whether what risk factors exist 
for developing asthma worldwide, their prevalence and frequency, while considering the 
nature of childhood febrile disorders, different medical practices, health behaviors, 
environment, and lifestyle. The overall GRADE of this study still is very low, with an 
overall significance rating of “critical.” 
In the Wickens et al42 study paracetamol questions were only asked at the 
Christchurch center in this study, so data was limited, study sample size was reduced to 
half. The Wellington center had already commenced the study and questionnaire portion 
prior to considering the paracetamol hypothesis. To ensure continuity of data from 
questionnaires in the event that participants had answered the questionnaire earlier or 
later than the target date, the recall period was changed to “since last telephone 
conversation”. No data was collected for indication of use of paracetamol in the first 15 
months, but data was independent of both lower respiratory tract infection and antibiotic 
use. When confounded for it still was not significantly significant. Imprecision was 
controlled for with exact definitions and categories for wheeze defined, and asthma 
diagnosed by a doctor. There was no collection of information on paracetamol exposure 
during pregnancy so this could have been confounding with recent studies suggesting 
increased risk of asthma with intra uterine use of paracetamol.12 Failure of this study to 
have a control population due to the nature of the study, probability of recall bias, not 
adequately confounding for indication of use of paracetamol in infancy, and lack of 
precision seen in the wide CI’s, this study received a downgrade from low at baseline 
because of its status as an observational study. 
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The possibility that later use of paracetamol in childhood may maintain asthma 
symptoms was demonstrated with this study, possibly explained by the glutathione 
mechanism earlier described.  Although not the primary outcome, it cannot be ignored. 
Reverse causation could contribute to positive associations if paracetamol were used to 
treat wheeze related illness. Or respiratory infection may have confounded, since they are 
independently associated with asthma and paracetamol use. Findings from this study raise 
concern about maintenance of asthma symptoms with current paracetamol use, direct 
causation in infancy has not been established due to the nature of the study. The quality 
of evidence in this study was given GRADE of very low, with an overall significance of 
“critical”. 
Shaheen et al40 significantly significant results were limited to those who had 
wheezed in infancy only. Asthma was defined when a doctor diagnosed the study child 
with asthma or wheezing in the past 12 months. An advantage to this study design was 
the use of propensity scores which reduced the number of model parameters which 
controlled for confounders to prevent potential nonconvergence of the regression models 
for infant exposure. The studies data were not complete on exposures, outcomes, or 
confounders for the whole cohort. Exclusion of children without complete information 
might have biased findings. Confounding by indication is of concern, it couldn’t be 
adjusted for because there was no data on indication for paracetamol use during infancy 
in this study because no one asked why the paracetamol was taken. The possibility that 
infant paracetamol exposure might contribute to maintenance of asthma symptoms should 
be considered, but the exposure and results would argue against a causal interpretation. 
This study confirmed a longitudinal association with childhood asthma, independent of 
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prenatal paracetamol exposure, it was limited or significant to children in the first 6 
months of life that had wheeze. Children who already had a wheeze tendency were more 
likely to be given paracetamol for viral respiratory infections with fever. The quality of 
evidence of this study was given a GRADE of very low, with an overall significance 
rating of “critical”. 
In review, due to the nature of the studies being observational without a control 
group, they were all downgraded to very low quality without the possibility of being 
upgraded even when considering all plausible confounders or dose response gradient 
magnitude of effect. Regardless of the GRADE criteria, recall bias and reverse causation 
need to be considered in the studies results. The large cross sectional study design is 
limiting in causal interpretation of paracetamol and asthma as well as observational 
studies have no direct causation due to the nature of the study. Children with wheeze 
associated with febrile illness and respiratory infection will be given paracetamol as an 
antipyretic, this should be considered as an important confounder by indication. 
CONCLUSION 
Further research is warranted. It is likely to have an important impact on the 
confidence in the estimate of effect and is likely to change the estimate. RCT are urgently 
required to determine whether associations are sufficiently causal to form basis for future 
recommendations for clinical practice in use of paracetamol in treatment of children. 
The results from the studies in this review are inconsistent. It is suggested that 
exposure to paracetamol in the first years of life might be a risk factor for the 
development of asthma in childhood and direct causation is still questionable. Consistent 
studies are needed that use a control group and the same confounders to account for 
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inconsistencies in the results of current studies. There is some suggestion from the results 
in this review that children with preexisting wheeze or asthma, and family history of 
atopy may be at greater risk for childhood asthma when using paracetamol early in life.  
At this point without further RCT studies, it is unknown if it is causative. Well conducted 
RCT studies are recommended to further explore the causes of childhood asthma and the 
risk factor of paracetamol exposure. 
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Table I. Characteristics of Reviewed Studies 
 
Quality Assessment 
Quality Importance 
No of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
Total days of paracetamol use (any indication) during early life and risk of asthma. Lowe et al. (follow-up 5-7 patient-years; assessed with: Adjusted for frequency of 
infections) 
1 observational studies serious1 no serious inconsistency no serious indirectness serious2 none ⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Total days of paracetamol use for fever during first year of life and risk of asthma. Beasley et al. (follow-up 6-7 patient-years; assessed with: Multivariate analysis 
complete covariate data only) 
1 observational studies serious3 serious4 no serious indirectness serious none ⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Paracetamol use before 15 months and outcome current asthma. Wickens et al. (follow-up 5-6 patient-years; assessed with: Adjusted for chest infections and antibiotic 
use.) 
1 observational studies serious5 no serious inconsistency serious6 serious7 none ⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Effects of infant acetaminophen use on childhood asthma. Shaheen et al. (follow-up 7.5 patient-years; assessed with: Adjusted for wheeze/no wheeze in first 6 months.) 
1 observational studies serious8 no serious inconsistency no serious indirectness no serious imprecision none ⊕ΟΟΟ 
VERY LOW 
CRITICAL 
1 Infant were eligible to be enrolled if one or more oftheir first degree family members had eczema, asthma, allergic rhinitis, severe food allergy. 
2 After adjustment for frequency of infections, not significant 1.08 (0.91-1.29). 
3 Failure to adequately control for confounding, no indication of use reported, and recall bias due to mutlticenter cross sectional study design.  
4 Paracetamol is marketed in combinations, and differently internationally, with off label use and dosing differences. 
5 No indication of use information gathered, or paracetamol exposure during pregnancy as a confounder. 
6 Variability in resluts with no explanation to the wide confidence intervals in study. 
7 Lack of precision with wide confidence intervals, sample size was reduced to half prior to questioning about paracetamol and the start of study. 
8 Recall bias, studies data not complete on exposures, outcomes, or confounders for the whole cohort. No indication of acetaminophen use during infancy. 
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Table II. Summary of Findings 
Summary of Findings 
Study Design Participants Age Paracetamol Exposure Age of Follow Up 
Adjustments 
 
Total days of paracetamol use (any indication) during early life and risk of asthma Unadjusted Adjusted for Standard Confounders1 
Adjusted for 
frequency of 
infections2 
Lowe et 
al 
Birth cohort 620 Up to 2 years with family hx 
of atopy 
5-7 years 1.18 (1.00 to 1.39) 1.16 (.98-1.38) 1.08 (0.91-1.29) 
Total days of paracetamol use (non respiratory causes) during early life and risk of asthma  
     .95 (.81-1.12) .95 (.80-1.12) .98 (.83-1.17) 
Total days of paracetamol use for fever during first year of life and risk of asthma  Adjusted3 Adjusted4 Multivariate5 
Beasley 
et al 
Multicenter Cross-
Sectional  205 487 First year of life 6-7 years 1.76 (1.68-1.85) 1.77 (1.66-1.89) 1.46 (1.36-1.56) 
Total days of paracetamol use for fever during first year of life and risk of severe asthma  
     1.82 (1.70-1.95) 1.82 (1.65-2.00) 1.43 (1.30-1.58) 
Paracetamol use before 15 months and outcome current asthma at 6 years Unadjusted Adjusted6  
Wickens 
et al Birth Cohort 469 Birth to 15 months 5-6 years 1.85 (.81-4.25) 1.78 (.75-4.21)  
Paracetamol use before 15 months and outcome of atopy and current asthma 
     3.35 (.77-14.25) 4.13 (.93-18.48)  
Paracetamol use before 15 months and outcome current asthma no atopy 
     1.51 (.43-5.22) 1.53 (.41-5.68)  
Effects of infant paracetamol use on childhood asthma Unadjusted Adjusted7  
Shaheen 
et al Birth Cohort 7735 Birth to 6 months 7.5 years 1.19 (1.08-1.32) 1.11 (1.00-1.23)  
Adjusted for wheeze/no wheeze in first 6 months and effects acetaminophen and childhood asthma No Wheeze Wheeze  
     1.03 (.92-1.16) 1.44 (1.13-1.83)  
1 Infant's sex, parental history of asthma, and presence of older siblings at time of birth 
2 Upper and lower respiratory tract infections, otitis media, and gastrointestinal infections during first 2 years of life 
3 Adjusted for sex, region of the world, language, and gross national income 
4 Adjusted, children with complete covariate data only, adjusted for sex, region of the world, language, and gross national income 
5 Multivariate analysis children with complete covariate data only, at least 70% data available for all covariates, children with missing data for any covariates 
removed 
6 Adjusted for number of chest infections before 15 months, antibiotic use before 15 months, gender, family history, parity, birth wt, maternal age, maternal 
smoker during pregnancy, any household smoking between birth and 15 months 
7 Adjusted for maternal factors in pregnancy, sex of child, season of birth, multiple pregnancy, gestational age, birth weight, head circumference, birth length, 
and postnatal factors 
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Appendix A  
 
ISAAC QUESTIONNAIRE SAMPLE  
 
Original Article: 
MI Asher, U Keil, HR Anderson, R Beasley, J Crane, F Martinez, EA Mitchell, N Pearce, 
B Sibbald, AW Stewart, D. Strachan, S.K. Weiland, H.C. Williams 
 
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and 
methods Eur Respir J March 1, 1995 8:483-491. 
 
MATERIAL: 
Table 4, 5 and 6 
 
 
 
 
 
* Reproduced with permission of the European Respiratory Society. Eur Respir J March 1, 1995 8:483-491. 
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*Reproduced with permission of the European Respiratory Society. Eur Respir J March 1, 1995 8:483-491. 
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